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Novelty and Impact. 
Reprogramming of neutrophils into an immunosuppressive phenotype has been reported in solid 





 immunosuppressive neutrophils in chronic lymphocytic leukemia 
(CLL) patients and show that leukemic B cells are responsible for inducing neutrophil 
reprogramming into this subset. Our findings shed light on the potential contribution of this 
subset to the impaired immune response exhibited by CLL patients and encourage their 
assessment as complementary therapeutic targets to improve patient’s outcome. 
 
Abstract. 
Reprogramming of neutrophils by malignant cells is well-described for many types of solid 
tumors, but data remain scarce for hematological diseases. Chronic lymphocytic leukemia 
(CLL) is characterized for a deep immune dysregulation mediated by leukemic cells that 
compromises patient’s outcome. Murine models of CLL highlight the relevance of myeloid cells 
as tumor-driven reprogramming targets. In this study, we evaluated neutrophil reprogramming 




 neutrophil subset in 
peripheral blood of CLL patients is increased compared to age-matched healthy donors (HD). In 
vitro, neutrophils from HD cultured in the presence of CLL cells or conditioned media (CM) 
from CLL cells exhibited a longer lifespan. Depletion of G- and GM-CSF from CM partially 





 phenotype was increased in the presence of CM from CLL cells, being TGF-
β/IL-10 responsible for this effect. Altogether our results describe a novel mechanism through 
which CLL cells can manipulate neutrophils.  
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Introduction 
The immune system, whose basic function is to protect the body from infection, undergoes a 
change towards immunosuppression in the context of cancer. In this process, tumor cells 
polarize different infiltrating leukocyte populations into a tumor growth promoting phenotype 
(1). Neutrophils constitute a significant part of the inflammatory infiltrate in many types of 
cancer (2-4) and high levels of intratumoral neutrophils have been associated with poor 
prognosis (5), as they would promote metastasis (6, 7) and angiogenesis (8). However, other 
studies have reported antitumor effects mediated by neutrophils, demonstrating that they are 
able to exhibit direct cytotoxic effects toward tumor cells (9) and to prevent metastasis (10).  
Reprogramming of neutrophils into tumor associated neutrophils (TANs) is well-described in 
the setting of solid tumors (3, 4, 11-13), but there are few reports related with TANs in the 
context of leukemia.  
Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of 
clonal B lymphocytes in blood, lymph nodes, spleen and bone marrow (14). Infections persist as 
the leading cause of morbidity and mortality in CLL patients, being bacterial infections the most 
frequent. The major cause of the high incidence of infections is dysregulation of the immune 
system, which is one of the main characteristics of CLL from early stages, worsening with the 
progression of the disease (15). Previous reports indicate that CLL cells were capable of 
modulating immune cell functions turning them into an immunosuppressive/tumor-supportive 
phenotype. Although almost every cell type in lymphoid tissues can be modified by the 
leukemic clone, myeloid cells are crucial to promote its progression as shown in the Eμ-TCL1 
mouse model of CLL(16). In this model, it was shown that spleen marginal zone neutrophils in 
contact with CLL cells had a longer lifespan and acquired a tumor-supportive phenotype (16). 
Recently, Manukyan et al reported that neutrophils from CLL patients exhibit a particular 
phenotype with reduced expression of TLR2 and LPS-induced release of proinflammatory 
cytokines(17). However the participation of leukemic cells in these neutrophil dysfunctions 
remains largely unknown. Herein we show that circulating CLL cells are able to induce 

















CLL patients and Healthy Donors (HD) samples. 
Peripheral blood samples were obtained from CLL patients (age range 50–75), and HD (age 
range 50-73) after informed consent in accordance with the Declaration of Helsinki (Clinical 
data from CLL-patients is depicted in supplementary table 1). These studies were approved by 
the Institutional Review Board of the Institutes of the National Academy of Medicine, Buenos 
Aires. At the time of the analysis patients were free from clinically relevant infectious 
complications and were either untreated or had not received antineoplastic treatment for ≥3 
months before the study began. 
Cell separation procedures and culture. 
Leukemic cells and neutrophils were isolated as we previously described (18).  
Neutrophils (2 x 10
6
/ml) were co-cultured with CLL cells (2 x 10
6
/ml) in RPMI medium 
supplemented with 10% fetal calf serum and antibiotics (Gibco-Thermo Fisher Scientific), 
during 72 h at 37°C. At 24, 48 and 72 h, samples were collected and stained with Annexin-V-
FITC (Biolegend) to assess neutrophil apoptosis by flow cytometry. HD-neutrophil samples 
used in co-cultures had <1% of lymphocytes and <0,5% of monocytes (CD14
+
). CLL-samples 
used in co-cultures were purified using a negative selection kit for CD19 cells (Miltenyi Biotec). 
CLL-Conditioned media (CM) were obtained culturing CLL cells (2 x 10
6
 cells/ml) during 48h.  
To reduce the levels of IL-10, G-CSF, GM-CSF or TGF-β in CM, it was incubated on plates 
coated with specific antibodies (anti-IL-10, anti-G-CSF and anti-GM-CSF purchased from 
Biolegend; anti-TGF-β from Thermo-Fisher) during 1h at room temperature. Cytokine depletion 
was confirmed by ELISA. 
To assess neutrophils immunosuppressive function, peripheral blood mononuclear cell from HD 
were activated with PHA (3µg/ml) for 24 h with or without HD-neutrophils or CLL-neutrophils 
(1:3 ratio). The expression of the activation marker CD69 was measured on T-cells by flow 
cytometry and the amount of INFγ released was quantified in culture supernatants by ELISA 
(Biolengend). 
Western blot. 
Whole-cell lysates were obtained from 10 × 10
6
 neutrophils, cultured or not in CM for 18h, 
using 120 µL of loading buffer 1× 5% β-mercaptoethanol with 2ul of Halt protease inhibitor 
cocktail (Thermo Scientific). Lysates were boiled at 99 °C for 5 min, and 50 µL of the protein 
extracts were separated on a standard 12% SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membranes. Membranes were then blotted with antibodies against Bfl-1 and 
followed by HRP-conjugated anti-rabbit IgG. Specific bands were developed by enhanced 
chemiluminescence (ECL) method. The same membrane was blotted with mAb anti-β-actin 










followed by HRP-conjugated anti-mouse IgG to compare the total amount of protein in each 
sample.  
Flow cytometry. 
Intracellular staining of Arginase I (PE-anti-ArgI; R&D, polyclonal IgG) was performed in 
whole blood samples fixed with PFA 1% for 15 minutes and permeabilized with PBS 0,1% 
saponin for 30 min. For surface staining FITC-Annexin-V, PerCP-Cy5.5-anti-CD16 (3G8), 
FITC-anti-CD16 (NPK15), PE-anti-CD62L (DREG-56), PerCP-Cy5.5-anti-CD62L (MEL-14) 
and PE-CD11b (ICRF44) were used, all of them purchased from BD-Biosciences.  
RNA Preparation, cDNA Synthesis and qRT-PCR. 
Total RNA Preparation, cDNA Synthesis and qRT-PCR Total RNA was extracted from 1 x 10
6
 
purified neutrophils using TRIzol reagent, and cDNA was generated by reverse transcription 
with MMLV RT according to the manufacturer´s instructions. qRT-PCR was performed using 
SYBR Green PCR Master Mix in 20 µl reactions. Primers were designed using Primer3 
software and purchased from Ruralex-Fagos: GAPDH Fw 5´GAGTCAACGGATTTGGTCGT 
3´, GAPDH Rv 5´-TTGATTTTGGAGGGATCTCG-3´, APRIL Fw 5´- 
CCTGGGACTTTGATTTTACGG-3´, APRIL Rv 5´-TGGTGGTGCTGTTCTGGATG-3´, 
BAFF Fw 5´-TGGTGACTTTGTTTCGATGTATTC-3´, BAFF Rv 5´-
GTTCATCTCCTTCTTCCAGTTTTG-3´ and were used at a concentration of 250 nM. 
Reactions were carried out in CFX Connect
TM
 real-time PCR detection system (Biorad). The 
cycling program used was 50 ˚C for 2 minutes, 95˚C for 1 minute, followed by 40 cycles of 
95˚C for 15 seconds, 60˚C for 60 seconds. Data were analyzed using GAPDH as a reference 
gene. 
Results and discussion 
Although most reports describe TANs differentiation at solid tumor microenvironment, recently 




) has been 
identified in patients with head and neck squamous cells carcinoma (HNSCC) (19). 
To determine if this neutrophil subset is also expanded in CLL patients, aliquots of fresh 
peripheral blood samples from age-matched HD and CLL patients were stained with anti-CD16 
and anti-CD62L antibodies and fixed immediately before erythrocytes lysis. This approach has 
been reported to prevent CD62L downregulation due to neutrophil manipulation (20). Clinical 
features of CLL patients evaluated are depicted in Supplementary Table 1. We found that CLL 




 neutrophil subset 
compared to age-matched HD samples (Fig 1 A-B). Although there was no statistically 




 neutrophils and any of the 
clinical parameters recorded, CLL patients with intermediate or advanced disease (Binet B and 










C stages) showed a strong trend towards higher proportion of TANs (Supplementary Fig 1). 
While future studies with a larger cohort of patients are necessary to corroborate these findings, 
they are in line with recent data from Manukyan et al who showed that active disease was 





 neutrophils expressed higher levels of CD11b (Fig 1.C). By 
contrast, we did not find differences in arginase 1 expression (Supplementary Fig 2), a known 






 neutrophils were reported to exert immunosuppressive activity on 
T cells (21), we next compared the capacity of neutrophils from HD and CLL patients to impair 
T cell activation. To that aim T lymphocytes from HD samples were stimulated with PHA in the 
presence of HD-neutrophils or CLL-neutrophils (1:3 T cell: neutrophil ratio). Twenty-four 
hours later, the expression of the activation marker CD69 on T cells and the release of interferon 
γ to the supernatant were recorded. Neutrophils from both sources were able to reduce PHA-
induced activation of T cells; however the inhibition was significantly higher in the presence of 
CLL neutrophils compared to HD neutrophils (Fig. 1 E-F). These results suggest that, as 
reported in gastric cancer (22), neutrophils from CLL patients can impair T cell responses. 
Because increased lifespan is crucial for neutrophils to acquire a TAN phenotype, we compared 
in vitro survival of neutrophils from HD and CLL patients. At 24 h, CLL neutrophils displayed 
a significantly higher survival that was not evident at longer times (Fig. 1 G).  
We next determined if CLL cells were responsible for the increased neutrophils survival by co-
culturing purified HD-neutrophils with or without CLL cells. Neutrophil viability was evaluated 
at 24, 48 and 72 h using Annexin V-FITC and flow cytometry analysis. Representative results 
are depicted in Figure 2 A-B. As expected when cultured alone, less than 40% of neutrophils 
(Annexin V
-
) were viable at 24 h. However, in the presence of CLL cells, a significant 
proportion of neutrophils remained viable even after 72 h in culture. To assess if this delay of 
neutrophil apoptosis could be attributed to cell-to-cell signals and/or to soluble factors, we 
performed co-cultures of neutrophils and CLL cells in transwell chambers. There were no 
significant differences in neutrophil viability between those separated from CLL cells by 
transwell membrane or mixed together, suggesting that soluble factors released by CLL cells 
might be responsible for neutrophil protection (Fig. 2C). Of note, B lymphocytes purified from 
age-matched- HD (>97% CD19+) were not able to rescue neutrophils from apoptosis suggesting 
that it is a feature of CLL cells (Fig. 2D). Since soluble factors released from CLL cells were 
responsible for the protective effects on neutrophils, we decided to use conditioned media (CM) 
from purified CLL cells in subsequent experiments. We first evaluated the involvement of GM-










CSF and G-CSF, two well-known factors released by CLL cells that are crucial to increase 
neutrophil lifespan (20). To that aim we cultured HD-neutrophils for 24 h with whole CM or 
CM depleted from GM-CSF and/or G-CSF before evaluating apoptosis. As shown in Fig 2E, 
depletion of both cytokines significantly though not completely counteracted the anti-apoptotic 
effect of CM suggesting that G- and GM-CSF released by leukemic cells were involved in 
increasing neutrophil lifespan. Additionally, since that IL-10 and TGF-β had been implicated in 
TANs reprogramming (23) we assessed their participation as antiapoptotic agents in CM. 
Depletion of both anti-inflammatory cytokines did not impair CM antiapoptotic effect (Fig 2F). 
Given that longer lifespan of TANs has been associated with increased expression of Bfl-1 (16, 
23), an anti-apoptotic member of the Bcl-2 family, we evaluated Bfl-1 expression on HD-
neutrophils exposed to CM. By western blot we found that   Bfl-1 levels were significantly up-
regulated in HD-neutrophils incubated for 18 h in CM compared to those incubated in control 
medium (Fig. 2G). 
Finally, we evaluated the expression of CD16 and CD62L in viable HD-neutrophils cultured in 
the presence of CM to determine if soluble factors released by malignant B cells were able to 
induce neutrophil reprogramming into TANs. Exposure of HD-neutrophils to CM for 24 h 




 subset. Even though IL-10 and TGF-
β were not involved in antiapoptotic effect of CM we assessed their participation in the 
downregulation of CD62L by depleting each or both cytokines from CM. As shown in Fig 3C, 
single depletions of IL-10 or TGF-β did not modify CM capacity to increase the percentage of 
CD62L
dim
 neutrophils. However, depletion of both cytokines significantly reduced 
reprogramming activity of CM suggesting a cooperative effect of IL-10 and TGF-β.   




 neutrophils in HNSCC 
correlates with better clinical outcome due to the antitumor activity exerted by these cells 
through the release of NETs. By contrast, we previously reported in CLL that NETs promote 





subset could be detrimental instead of beneficial to CLL patients. 
Neutrophils displaying a            B-helper phenotype have been previously described (24) at the 
marginal zone of the spleen where IL-10 released by activated endothelial cells enable 
neutrophils to produce BAFF, APRIL and NET-like structures that promote B-cell activation. 
Although we did not observe a BAFF or APRIL differential expression between circulating 





 cells receive additional signals from the microenvironment to 
promote leukemic B cell survival. This hypothesis is supported by a previous report in the Ɛµ-
TCL1 murine model of CLL that showed an expanded neutrophil population with B-helper 
properties in the spleen of leukemic mice which does not exist in the bone marrow (16), 










suggesting that the local environment is critical for shaping the gene expression program of B 
helper neutrophils.  
Here we described the capacity of CLL cells to reprogram circulating neutrophils into a tumor-




 subset may influence CLL 
patient outcome not only by favoring leukemic cell survival through NETs release, but also by 
impairing T-cell responses with increased risk of infectious complications.  
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Novelty & Impact Statement: 
 
The reprogramming of neutrophils into an immunosuppressive phenotype is known to occur in 
the solid tumor microenvironment. The present study shows that this phenomenon also exists 
in a hematological disease, wherein an increased percentage of circulating immunosuppressive 
neutrophils, namely the CD16highCD62Ldim subset, was identified in chronic lymphocytic 
leukemia (CLL) patients. Cooperative effects of the soluble factors IL-10 and TGFβ, released 
from leukemic B cells, appear to play a role in neutrophil reprogramming into the 
CD16highCD62Ldim subset. The findings shed light on the potential contribution of neutrophil 
reprogramming to the impaired immune response exhibited by CLL patients. 
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